Irish medtech company Neuromod is to begin offering its Irish-made Lenire tinnitus treatment medical device in the United Kingdom and Switzerland, in what is a major European expansion for the company.
The move will make the treatment available to tinnitus sufferers in the UK through its partnership with the Tinnitus Clinic, and in Switzerland where it has linked up with 10 clinical partners throughout the country, in places such as Geneva, Bern and Basel. It has also established a telemedicine service, which offers assessments to potential patients online.
The company estimates that about eight million people across the two countries suffer from the condition.
Tinnitus is a chronic condition that is understood to affect up to 15 per cent of the world’s population. It is commonly described as a ringing in the ears.
Neuromod has developed a non-invasive device, Lenire, that delivers sound to the ears and electrical stimulation to the tongue. It is prescribed and fitted under the supervision of a qualified healthcare professional.
"As the company has scaled up over the past 12 months, as well as our operations in Ireland, Germany, Austria and Belgium, we've been focusing on the logistical challenges of making Lenire available to patients in as many European countries as possible," said Dr Ross O'Neill, CEO of Neuromod Devices.
“We had been treating a small number of UK-resident patients via our telemedicine service, so it’s good to be able to expand the provision of our services and the Lenire device in these countries.”
Service
The telemedicine service is delivered through Neuromod Medical, based at the Hermitage Medical Clinic in Dublin. The company last year opened its German office, and has since signed up 57 partners who make the device, with its treatment plan available in 96 clinics throughout Germany. Neuromod also has three partner clinics in Austria.
“Finding an effective and long-lasting treatment for tinnitus has been a source of stress for tinnitus patients around the world for a long time. Recently, with tinnitus being a common symptom of ‘long Covid’, the demand for an effective tinnitus therapy has increased,” Dr O’Neill said.
“At Neuromod, our goal with Lenire is to improve the quality of life of those suffering from tinnitus and this is what motivates us to bring this treatment to as many people as we can. The results of large-scale clinical trials, involving more than 500 participants, are very positive, as are the real-world outcomes for our patients in Ireland and Germany so this is a very exciting time for the company.”
In October, Neuromod raised €10.5 million to fund the company’s expansion.
